Bacterial gene therapy strategies

Journal of Pathology

Volumn 208, Issue 2, 2006, Pages 290-298

  Vassaux, Georges ^a   Nitcheu, Josianne ^a   Jezzard, Sarah ^a   Lemoine, Nick R ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Bacteria; Cancer; Gene therapy; Inflammatory bowel disease; Listeria; Salmonella; Shigella; Vaccination; Yersinia

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; BACTERIAL ANTIGEN; BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; BETA GALACTOSIDASE; BIOLOGICAL PRODUCT; CISPLATIN; CYTOKINE; CYTOSINE DEAMINASE; DNA; DNA VACCINE; FLAGELLIN; FLUCYTOSINE; FLUOROURACIL; GLYCOPROTEIN GP 100; INTERLEUKIN 18; LIPOPROTEIN; LISTERIOLYSIN; NITROREDUCTASE; OUTER MEMBRANE PROTEIN; PRODRUG; SELENIUM; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FRA 1; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ANTIGEN; VNP 20009;

BACTERIAL CELL; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VECTOR; BIFIDOBACTERIUM LONGUM; CANCER IMMUNOTHERAPY; CLOSTRIDIUM; CLOSTRIDIUM NOYVI; DNA TRANSFER; ENTERITIS; ESCHERICHIA COLI; EXPERIMENTAL MODEL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION; LISTERIA; MAMMAL CELL; MICROBIAL ATTENUATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALMONELLA; SHIGELLA; VACCINATION; YERSINIA;

ANTIGENS, BACTERIAL; ANTIGENS, VIRAL; BACTERIA; CHROMOSOMES, ARTIFICIAL, BACTERIAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ACTIVE; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; RNA, SMALL INTERFERING; VACCINATION;

EID: 31144460811     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1865     Document Type: Review

References (99)

1. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
2. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nature Rev Genet 2005;6:299-310.
3. Heinemann JA, Sprague GF Jr. Bacterial conjugative plasmids mobilize DNA transfer between bacteria and yeast. Nature 1989;340:205-209.
4. Lessl M, Lanka E. Common mechanisms in bacterial conjugation and Ti-mediated T-DNA transfer to plant cells. Cell 1994;77:321-324.
5. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995;270:299-302.
6. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J, et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997;91:765-775.
7. Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 1998;92:3172-3176.
8. Dietrich G, Bubert A, Gentschev I, Sokolovic Z, Simm A, Catic A, et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nature Biotechnol 1998;16:181-185.
9. Grillot-Courvalin C, Goussard S, Huetz F, Ojcius DM, Courvalin P. Functional gene transfer from intracellular bacteria to mammalian cells. Nature Biotechnol 1998;16:862-866.
10. Grillot-Courvalin C, Goussard S, Courvalin P. Bacteria as gene delivery vectors for mammalian cells. Curr Opin Biotechnol 1999;10:477-481.
11. Loessner H, Weiss S. Bacteria-mediated DNA transfer in gene therapy and vaccination. Expert Opin Biol Ther 2004;4:157-168.
12. Marra A, Isberg RR. Common entry mechanisms. Bacterial pathogenesis. Curr Biol 1996;6:1084-1086.
13. Goussard S, Grillot-Courvalin C, Courvalin P. Eukaryotic promoters can direct protein synthesis in Gram-negative bacteria. J Mol Microbiol Biotechnol 2003;6:211-218.
14. Grillot-Courvalin C, Goussard S, Courvalin P. Wild-type intracellular bacteria deliver DNA into mammalian cells. Cell Microbiol 2002;4:177-186.
15. Portnoy DA, Chakraborty T, Goebel W, Cossart P. Molecular determinants of Listeria monocytogenes pathogenesis. Infect Immun 1992;60:1263-1267.
16. Isberg RR, Leong JM. Multiple beta 1 chain integrins are receptors for invasin, a protein that promotes bacterial penetration into mammalian cells. Cell 1990;60:861-871.
17. Critchley RJ, Jezzard S, Radford KJ, Goussard S, Lemoine NR, Grillot-Courvalin C, et al. Potential therapeutic applications of recombinant, invasive E. coli. Gene Ther 2004;11:1224-1233.
18. Radford KJ, Higgins DE, Pasquini S, Cheadle EJ, Carta L, Jackson AM, et al. A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: application to cancer immunotherapy. Gene Ther 2002;9:1455-1463.
19. Radford KJ, Jackson AM, Wang JH, Vassaux G, Lemoine NR. Recombinant E. coli efficiently delivers antigen and maturation signals to human dendritic cells: presentation of MART1 to CD8+ T cells. Int J Cancer 2003;105:811-819.
20. Fajac I, Grosse S, Collombet JM, Thevenot G, Goussard S, Danel C, et al. Recombinant Escherichia coli as a gene delivery vector into airway epithelial cells. J Control Release 2004;97:371-381.
21. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
22. Poltorak A, Ricciardi-Castagnoli P, Citterio S, Beutler B. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci U S A 2000;97:2163-2167.
23. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-2088.
24. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
25. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001;167:1882-1885.
26. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, et al. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 1999;285:736-739.
27. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine 1997;15:804-807.
28. Al-Mariri A, Tibor A, Lestrate P, Mertens P, De Bolle X, Letesson JJ. Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen. Infect Immun 2002;70:1915-1923.
29. Bauer H, Darji A, Chakraborty T, Weiss S. Salmonella-mediated oral DNA vaccination using stabilized eukaryotic expression plasmids. Gene Ther 2005;12:364-372.
30. Darji A, zur Lage S, Garbe AI, Chakraborty T, Weiss S. Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol Med Microbiol 2000; 27:341-349.
31. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981;291:238-239.
32. Pasetti MF, Anderson RJ, Noriega FR, Levine MM, Sztein MB. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin Immunol 1999;92:76-89.
33. Woo PC, Wong LP, Zheng BJ, Yuen KY. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine 2001;19:2945-2954.
34. Zheng BJ, Ng MH, Chan KW, Tam S, Woo PC, Ng SP, et al. A single dose of oral DNA immunization delivered by attenuated Salmonella typhimurium down-regulates transgene expression in HBsAg transgenic mice. Eur J Immunol 2002;32:3294-3304.
35. Wedemeyer H, Gagneten S, Davis A, Bartenschlager R, Feinstone S, Rehermann B. Oral immunization with HCV-NS3-transformed Salmonella:induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 2001;121:1158-1166.
36. Flo J, Tisminetzky S, Baralle F. Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice. Vaccine 2001;19:1772-1782.
37. Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol 2004;78:12901-12909.
38. Baud D, Benyacoub J, Revaz V, Kok M, Ponci F, Bobst M, et al. Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium. Infect Immun 2004;72:750-756.
39. Shata MT, Hone DM. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity. J Virol 2001;75:9665-9670.
40. Shata MT, Reitz MS Jr, DeVico AL, Lewis GK, Hone DM. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 2001;20:623-629.
41. Vecino WH, Morin PM, Agha R, Jacobs WR Jr, Fennelly GJ. Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunol Lett 2002;82:197-204.
42. Xu F, Hong M, Ulmer JB. Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella. Vaccine 2003;21:644-648.
43. Pasetti MF, Barry EM, Losonsky G, Singh M, Medina-Moreno SM, Polo JM, et al. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats. J Virol 2003;77:5209-5217.
44. Vecino WH, Quanquin NM, Martinez-Sobrido L, Fernandez-Sesma A, Garcia-Sastre A, Jacobs WR Jr, et al. Mucosal immunization with attenuated Shigella flexneri harboring an influenza hemagglutinin DNA vaccine protects mice against a lethal influenza challenge. Virology 2004;325:192-199.
45. Shiau AL, Chu CY, Su WC, Wu CL. Vaccination with the glycoprotein D gene of pseudorabies virus delivered by nonpathogenic Escherichia coli elicits protective immune responses. Vaccine 2001;19:3277-3284.
46. Shiau AL, Chen YL, Liao CY, Huang YS, Wu CL. Prothymosin alpha enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis. Vaccine 2001;19:3947-3956.
47. Zoller M, Christ O. Prophylactic tumor vaccination: comparison of effector mechanisms initiated by protein versus DNA vaccination. J Immunol 2001;166:3440-3450.
48. Cochlovius B, Stassar MJ, Schreurs MW, Benner A, Adema GJ. Oral DNA vaccination: antigen uptake and presentation by dendritic cells elicits protective immunity. Immunol Lett 2002;80:89-96.
49. Weth R, Christ O, Stevanovic S, Zoller M. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination. Cancer Gene Ther 2001;8:599-611.
50. Xiang R, Lode HN, Chao TH, Ruehlmann JM, Dolman CS, Rodriguez F, et al. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci U S A 2000;97:5492-5497.
51. Lode HN, Pertl U, Xiang R, Gaedicke G, Reisfeld RA. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med Pediatr Oncol 2000;35:641-646.
52. Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA. Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 2003;101:649-654.
53. Xiang R, Primus FJ, Ruehlmann JM, Niethammer AG, Silletti S, Lode HN, et al. A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenc mice. J Immunol 2001;167:4560-4565.
54. Luo Y, Zhou H, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci U S A 2003;100:8850-8855.
55. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature Med 2002;8:1369-1375.
56. Feng KK, Zhao HY, Qiu H, Liu JX, Chen J. Combined therapy with flk1-based DNA vaccine and interleukin-12 results in enhanced antiangiogenic and antitumor effects. Cancer Lett 2005;221:41-47.
57. Mose JR, Mose G. Oncolysis by Clostridia. I. Activation of Clostridium bytiricum (M-55) and other nonpathogenic Clostridia against the Ehrlich sarcoma. Cancer Res 1964;24:212-216.
58. Thiele EH, Arison RN, Boxer GE. Oncolysis by Clostridia. III. Effects of Clostridia and chemotherapeutic agents on rodent tumors. Cancer Res 1964;24:222-231.
59. Engelbart K, Gericke D. Oncolysis by Clostridia. V. Transplanted tumors of the hamster. Cancer Res 1964;24:239-243.
60. Carey RW, Holland JF, Whang HY, Netter E, Bryant B. Clostridial oncolysis in man. Eur J Cancer 1967;3:37-46.
61. Lemmon MJ, van Zijl P, Fox ME, Mauchline ML, Giaccia AJ, Minton NP, et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther 1997;4:791-796.
62. Fox ME, Lemmon MJ, Mauchline ML, Davis TO, Giaccia AJ, Minton NP, et al. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered Clostridia. Gene Ther 1996;3:173-178.
63. Minton NP. Clostridia in cancer therapy. Nature Rev Microbiol 2003;1:237-242.
64. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 2002;9:291-296.
65. Theys J, Landuyt W, Nuyts S, Van Mellaert L, van Oosterom A, Lambin P, et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 2001;8:294-297.
66. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Bosmans E, Anne J, et al. Radio-responsive recA promoter significantly increases TNFalpha production in recombinant Clostridia after 2 Gy irradiation. Gene Ther 2001;8:1197-1201.
67. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 2001;98:15155-15160.
68. Dang LH, Bettegowda C, Agrawal N, Cheong I, Huso D, Frost P, et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004;3:326-337.
69. Bettegowda C, Dang LH, Abrams R, Huso DL, Dillehay L, Cheong I, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A 2003;100:15 083-15 088.
70. Agrawal N, Bettegowda C, Cheong I, Geschwind JF, Drake CG, Hipkiss EL, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A 2004;101:15 172-15 177.
71. Kimura NT, Taniguchi S, Aoki K, Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 1980;40:2061-2068.
72. Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ, et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003;10:105-111.
73. Fu GF, Li X, Hou YY, Fan YR, Liu WH, Xu GX. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther 2005;12:133-140.
74. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997;57:4537-4544.
75. Luo X, Li Z, Lin S, Le T, Ittensohn M, Bermudes D, et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res 2000;12:501-508.
76. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nature Biotechnol 1999;17:37-41.
77. Pawelek JM, Sodi S, Chakraborty AK, Platt JT, Miller S, Holden DW, et al. Salmonella pathogenicity island-2 and anticancer activity in mice. Cancer Gene Ther 2002;9:813-818.
78. Kuhle V, Hensel M. Cellular microbiology of intracellular Salmonella enterica:functions of the type III secretion system encoded by Salmonella pathogenicity island 2. Cell Mol Life Sci 2004;61:2812-2826.
79. Platt J, Sodi S, Kelley M, Rockwell S, Bermudes D, Low KB, et al. Antitumour effects of genetically engineered Salmonella in combination with radiation. Eur J Cancer 2000;36:2397-2402.
80. Lee CH, Wu CL, Tai YS, Shiau AL. Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. Mol Ther 2005;11:707-716.
81. Lee CH, Wu CL, Shiau AL. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 2004;6:1382-1393.
82. Lee CH, Wu CL, Shiau AL. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther 2005;12:175-184.
83. Soghomonyan SA, Doubrovin M, Pike J, Luo X, Ittensohn M, Runyan JD, et al. Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther 2005;12:101-108.
84. Tjuvajev J, Blasberg R, Luo X, Zheng LM, King I, Bermudes D. Salmonella-based tumor-targeted cancer therapy: tumor amplified protein expression therapy (TAPET) for diagnostic imaging. J Control Release 2001;74:313-315.
85. Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 2005;11:4827-4834.
86. Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 2000;181:1996-2002.
87. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002;20:142-152.
88. Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, et al. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003;10:737-744.
89. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-1355.
90. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nature Biotechnol 2003;21:785-789.
91. Shanahan F. Making microbes work for mankind - clever trick or a glimpse of the future for IBD treatment? Gastroenterology 2004;127:667-668.
92. Castagliuolo I, Beggiao E, Brun P, Barzon L, Goussard S, Manganelli R, et al. Engineered E. coli delivers therapeutic genes to the colonic mucosa. Gene Ther 2005;12:1070-1078.
93. Narayanan K, Warburton PE. DNA modification and functional delivery into human cells using Escherichia coli DH10B. Nucleic Acids Res 2003;31:e51.
94. Laner A, Goussard S, Ramalho AS, Schwarz T, Amaral MD, Courvalin P, et al. Bacterial transfer of large functional genomic DNA into human cells. Gene Ther 2005;12:1559-1572.
95. Cicin-Sain L, Brune W, Bubic I, Jonjic S, Koszinowski UH. Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo. J Virol 2003;77:8249-8255.
96. Karagiannis TC, El-Osta A. RNA interference and potential therapeutic applications of short interfering RNAs. Cancer Gene Ther 2005;12:787-795.
97. Timmons L, Fire A. Specific interference by ingested dsRNA. Nature 1998;395:854.
98. Timmons L, Court DL, Fire A. Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans. Gene 2001;263:103-112.
99. Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM. AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 2001;92:641-650.